查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012930

良性前列腺增生治療市場：2026-2032年全球市場預測（依治療方法、產品類型、最終用戶和通路分類）

Benign Prostatic Hyperplasia Treatment Market by Treatment Type, Product Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

良性攝護腺增生 (BPH) 治療市場預計到 2025 年將達到 92 億美元，到 2026 年將成長到 97.4 億美元，到 2032 年將達到 139.6 億美元，年複合成長率為 6.12%。

主要市場統計數據
基準年 2025 92億美元
預計年份：2026年 97.4億美元
預測年份 2032 139.6億美元
複合年成長率 (%) 6.12%

探索新的臨床進展和市場促進因素，這些進展和因素將定義良性前列腺增生治療的下一個範式。

良性前列腺增生（BPH）因其在老年男性族群中的高發病率及其對生活品質（QOL）的顯著影響，已成為重要的臨床關注領域。隨著人口結構向老齡化患者的轉變加速，全球醫療保健系統面臨越來越大的壓力，需要提供安全、有效且經濟的治療方案。近年來，臨床創新、患者偏好和不斷變化的醫療保險報銷機制之間的相互作用，在一定程度上重新定義了與BPH相關的中重度下泌尿道症狀的治療目標。

確定將重塑良性前列腺增生症治療方法和患者療效的根本技術和監管變革。

良性前列腺增生（BPH）的治療格局正在經歷一場翻天覆地的變革，這主要得益於技術突破和監管環境的變化。傳統的治療方法主要依賴藥物治療和經尿道前列腺切除術，而如今，我們正見證著尖端能量治療方法、影像引導介入治療和標靶栓塞術的湧現。這些創新旨在最大限度地減少手術相關併發症，同時盡可能保留患者的泌尿和性功能，這正是當今患者群體最關注的問題。

分析美國關稅調整對良性前列腺增生症治療的可近性、供應鏈和創新途徑的綜合影響。

美國宣布的2025年關稅調整正在對全球供應鏈產生連鎖反應，影響良性前列腺增生（BPH）治療關鍵組件的成本結構和供應。許多醫療設備，從導管和電切鏡到泌尿系統雷射和植入，都源自海外或包含海外製造的組件。隨著進口關稅的提高，經銷商和醫療服務提供者面臨採購成本增加的困境，這影響了價格談判和報銷協商。

深入了解良性前列腺增生 (BPH) 的治療類型、產品類型、最終用戶和分銷管道的詳細細分，從而影響其管理方法。

對市場區隔的深入理解揭示了策略投資和產品開發的關鍵轉折點。考慮到治療方法方案，藥物治療仍然至關重要，其中5α還原酶抑制劑和α阻斷劑是首選治療方案。然而，微創治療，包括前列腺動脈栓塞術和蒸氣療法，由於恢復時間短、安全性高，正迅速普及。同時，外科治療也不再局限於傳統的經經尿道前列腺切除術，而是擴展到雷射手術、前列腺尿道提升術和經尿道切開術等，所有這些手術都以最大程度減少組織損傷為目標。

評估北美、歐洲、中東和非洲以及亞太地區市場趨勢的區域差異，並為良性前列腺增生 (BPH) 的標靶治療策略做出貢獻。

區域趨勢在良性前列腺增生症的治療生態系統中發揮著至關重要的作用，每個地區都有其獨特的監管、臨床和經濟考量。在美洲，健全的醫保報銷體系和技術的早期應用，以及廣泛的臨床試驗網路和成熟的支付方-醫療服務提供方合作關係，正在推動基於醫療設備的治療方法和先進藥物療法的快速普及。

本報告重點介紹了良性前列腺增生 (BPH) 治療領域領先的生物製藥、醫療設備和技術公司的創新策略、夥伴關係和競爭趨勢。

良性前列腺增生（BPH）領域的競爭格局呈現出老牌製藥公司和創新醫療設備製造商並存的局面。大型製藥企業憑藉其在5α-還原酶抑制劑和α阻斷劑領域數十年的產品系列經驗，佔據市場主導地位；而相關的生物製藥公司則致力於探索能夠同時緩解症狀和促進組織重塑的新型聯合治療。

制定切實可行的策略建議，以提高良性前列腺增生治療的臨床療效、市場滲透率和患者接受度。

具有前瞻性的產業領導者應優先考慮採取多管齊下的策略，以在不斷發展的良性前列腺增生市場中保持競爭優勢。首先，投資下一代微創技術，特別是那些適用於門診和診所環境的技術，將滿足患者對縮短復原時間和提高生活品質的需求。與關鍵意見領袖 (KOL) 和病例較多的醫療機構合作開展試驗計畫，可以加快技術推廣應用，並產生令人信服的真實世界證據，從而支持醫保報銷談判。

為確保良性前列腺增生市場評估研究結果的可靠性，詳細闡述了嚴格的資料收集、分析和檢驗協議。

本研究採用嚴謹的調查方法，結合了全面的二手資料研究、針對性的一手訪談和資料三角驗證。首先，我們系統地分析了同行評審期刊、監管資料庫、專利申請和行業白皮書，以建立治療方法、醫療設備創新和政策趨勢的可靠基準。我們整理了以往的監管核准和指南修訂情況，以確定關鍵市場變化的時機和範圍。

本研究整合了關鍵發現和策略意義，以確定良性前列腺增生治療領域未來的方向和機會。

主要研究結果總結表明，市場正經歷重大變革。微創療法的進步、監管路徑的協調統一以及關稅趨勢帶來的供應鏈考量日益增加，正在重塑治療流程和競爭動態。細分市場分析凸顯了非手術干預和專科產品類型的重要性日益成長，而區域洞察則強調了在美洲、歐洲、中東和非洲以及亞太地區製定量身定做的打入市場策略的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 良性攝護腺增生治療市場（依治療方法分類）

  • 藥物治療
    • 5α-還原酶抑制劑
    • α受體阻斷劑
  • 微創治療
    • 攝護腺動脈栓塞術
    • 蒸氣療法
  • 手術治療
    • 雷射手術
    • 攝護腺尿道拉提手術
    • 經尿道前列腺切開術
    • 經尿道前列腺切除術

第9章 良性攝護腺增生治療市場：依產品類型分類

  • 導管
  • 電極
  • 植入
  • 攝護腺支架
  • 電切鏡
  • 泌尿系統雷射

第10章 良性攝護腺增生治療市場：依最終使用者分類

  • 門診手術中心
  • 診所
  • 居家照護
  • 醫院

第11章 良性攝護腺增生治療市場：依通路分類

  • 離線
  • 線上

第12章 良性攝護腺增生治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 良性攝護腺增生治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 良性攝護腺增生治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國良性攝護腺增生治療市場

第16章：中國良性攝護腺增生治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alembic Pharmaceuticals Limited
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Cipla Ltd.
  • Coloplast Group
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Endo International PLC
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • IPG Photonics Corporation
  • Lumenis Ltd.
  • Olympus Corporation
  • Organon group of companies
  • PROCEPT BioRobotics Corporation
  • ProstaLund AB
  • Quanta System
  • Richard Wolf GmbH
  • Teleflex Incorporated
  • Urologix, LLC.
Product Code: MRR-437D4595848A

The Benign Prostatic Hyperplasia Treatment Market was valued at USD 9.20 billion in 2025 and is projected to grow to USD 9.74 billion in 2026, with a CAGR of 6.12%, reaching USD 13.96 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.20 billion
Estimated Year [2026] USD 9.74 billion
Forecast Year [2032] USD 13.96 billion
CAGR (%) 6.12%

Exploring the Emerging Clinical Developments and Market Drivers Defining the Next Generation of Benign Prostatic Hyperplasia Treatment Paradigms

Benign prostatic hyperplasia (BPH) has emerged as a critical area of clinical focus due to its high prevalence among aging male populations and its profound impact on quality of life. As the demographic shift towards an older patient base accelerates, healthcare systems worldwide face mounting pressure to deliver safe, effective, and cost-efficient interventions. In recent years, the interplay of clinical innovation, patient preference, and evolving reimbursement pathways has partially redefined treatment objectives for moderate to severe lower urinary tract symptoms associated with prostatic enlargement.

The clinical pipeline now features an expanding array of pharmacotherapies aimed at both symptom relief and underlying disease modification. Novel agents targeting androgen pathways, inflammatory mediators, and smooth muscle tone within the prostate are under active investigation. Concurrently, minimally invasive technologies have transitioned from niche options to mainstream considerations, offering shorter recovery times and preserved sexual function relative to traditional surgical approaches. Moreover, professional guidelines have begun to integrate these advancements, urging a more personalized treatment algorithm based on symptom severity, prostate volume, and patient comorbidities.

Consequently, stakeholders across the public and private sectors are aligning around a paradigm that balances clinical efficacy with patient-centric factors such as procedure durability, side effect profiles, and access to care. This introduction sets the stage for an in-depth exploration of how recent clinical developments and market drivers converge to define the next generation of BPH treatment paradigms.

Identifying the Fundamental Technological and Regulatory Transformations Reshaping Treatment Modalities and Patient Outcomes in Prostatic Enlargement Management

The landscape of benign prostatic hyperplasia treatment is undergoing profound transformation driven by both technological breakthroughs and shifting regulatory frameworks. Historically dominated by heavy reliance on pharmacotherapy and transurethral resection surgery, the field now witnesses the rise of cutting-edge energy-based modalities, image-guided interventions, and targeted embolic therapies. These innovations aim to minimize procedural morbidity while preserving urinary and sexual function, key priorities for today's patient cohorts.

On the regulatory front, health authorities have begun to streamline pathways for minimally invasive medical devices and combination regimens, reflecting an increased willingness to consider surrogate endpoints and patient-reported outcomes. Harmonization efforts across major markets are reducing approval timelines for technologies that demonstrate safety and performance in robust clinical studies. Furthermore, the integration of real-world evidence into post-market surveillance has accelerated iterative improvements, enabling manufacturers to refine device designs and procedural techniques at an unprecedented pace.

As a result, treatment modalities once considered experimental are gaining momentum in routine practice. The convergence of technology, regulation, and patient-centered care is reshaping the fundamental approach to prostatic enlargement management. This section delves into these transformative forces, highlighting how they coalesce to create new opportunities for improved patient outcomes and streamlined clinical pathways.

Analyzing the Converging Effects of United States Tariff Adjustments on Treatment Access Supply Chains and Innovation Paths for Prostatic Hyperplasia Care

United States tariff adjustments announced in 2025 have generated ripple effects across global supply chains, impacting the cost structures and accessibility of key benign prostatic hyperplasia treatment components. Many medical devices-ranging from catheters and resectoscopes to urology lasers and implants-originate from or incorporate parts manufactured abroad. As import duties rise, distributors and healthcare providers confront increased procurement expenses, which in turn influence pricing negotiations and reimbursement discussions.

Manufacturers have responded by reassessing their production footprints, exploring near-sourcing strategies, and renegotiating supplier contracts to mitigate steep cost escalations. Simultaneously, emerging trade agreements and tariff exemptions for certain medical goods have provided limited relief, though administrative burdens remain substantial. Consequently, device innovators must balance the imperative to maintain margins with the need to ensure equitable patient access, particularly in outpatient and ambulatory surgical center settings.

Looking ahead, the tariff environment is likely to catalyze broader supply chain resilience measures within the industry. Strategic collaborations and investment in localized manufacturing are expected to gain prominence as companies seek to insulate their operations from future policy shifts. This analysis examines how recent tariff modifications are redefining procurement, distribution, and innovation pathways for prostatic hyperplasia care.

Uncovering Granular Treatment Type Product End User and Distribution Channel Segmentation Insights Shaping Approaches to Prostatic Hyperplasia Management

A nuanced understanding of market segmentation reveals critical inflection points for strategic investment and product development. When treatment type is considered, medications continue to hold foundational importance, with 5-alpha-reductase inhibitors and alpha blockers serving as first-line pharmacologic interventions. Yet the minimally invasive therapy segment, encompassing prostate artery embolization and water vapor therapy, is rapidly gaining traction due to shorter recovery times and favorable safety profiles. At the same time, surgical treatments have diversified beyond traditional transurethral resection of the prostate, now including laser surgery, prostatic urethral lift, and transurethral incision techniques that prioritize minimal tissue disruption.

Examining product type segmentation highlights the essential role of supporting technologies. Catheters, electrodes, and resectoscopes remain indispensable for interventional procedures, while prostatic stents and specialized urology lasers are becoming increasingly sophisticated in their design and application. Each category presents distinct development pathways, driven by evolving clinical requirements and user feedback from surgeons and interventional radiologists.

End-user analysis further clarifies market dynamics, as ambulatory surgical centers gain preference for office-based procedures while hospitals maintain their position in complex surgical cases. Clinics offering pharmacotherapy and minimally invasive office procedures are expanding service portfolios, and homecare models for medication management and post-procedure monitoring are on the rise. Finally, distribution channel trends underscore a transition from traditional hospital procurement networks toward integrated online platforms that streamline ordering, enable real-time inventory management, and support remote training modules for new devices.

Evaluating Geographic Market Variations Across Americas Europe Middle East Africa and Asia Pacific to Inform Targeted Prostatic Hyperplasia Treatment Strategies

Regional dynamics play a pivotal role in shaping the benign prostatic hyperplasia treatment ecosystem, with each geography presenting unique regulatory, clinical, and economic considerations. In the Americas, robust reimbursement frameworks and early technology adoption drive rapid integration of both device-based therapies and advanced pharmacologics, supported by extensive clinical trial networks and established payer-provider collaborations.

In Europe, Middle East & Africa, diverse healthcare infrastructures foster a dual focus on cost containment and equitable access. Regulatory harmonization across the European Union facilitates cross-border device approvals, while emerging markets in the Middle East and Africa prioritize capacity building for minimally invasive techniques, often through international partnerships and training programs.

Across the Asia-Pacific region, accelerating population aging and growing awareness of male health issues are creating a surge in demand for both first-line medications and new procedural options. Governments are increasingly incentivizing local manufacturing and public-private research collaborations to expand access in less penetrated markets. Consequently, regional strategies must be tailored to navigate variations in clinical practice, reimbursement policies, and patient expectations across these diverse territories.

Highlighting Innovative Strategies Partnerships Competitive Dynamics Among Leading Biopharmaceutical Device Technology Companies in Prostatic Hyperplasia Care

Competitive dynamics in the benign prostatic hyperplasia arena are defined by a blend of established pharmaceutical firms and innovative device manufacturers. Leading drug makers leverage decades of portfolio experience in 5-alpha-reductase inhibitors and alpha blockers, while adjacent biopharma players explore novel combination therapies that address both symptom relief and tissue remodeling.

On the device side, global medical technology organizations continue to refine energy-based platforms, offering improved precision and reduced procedural times. Strategic partnerships between device innovators and contract research organizations have accelerated clinical validation, helping to secure favorable regulatory designations. At the same time, emerging companies specialize in niche delivery systems such as water vapor and embolic therapies, carving out competitive positions through targeted clinical data and differentiated user experiences.

The convergence of digital health and urology has also given rise to integrated software solutions that support pre-procedure planning, remote follow-up, and patient-reported outcome tracking. Consequently, the competitive field extends beyond core product offerings to encompass service ecosystems and data analytics capabilities that enhance long-term value for providers and patients alike.

Formulating Actionable Strategic Recommendations to Enhance Clinical Effectiveness Market Penetration and Patient Adoption in Prostatic Hyperplasia Treatment

Forward-looking industry leaders should prioritize a multifaceted approach to maintain competitive advantage in the evolving benign prostatic hyperplasia market. First, investing in next-generation minimally invasive technologies-particularly those with outpatient or office-based application-will address patient demand for reduced recovery times and preserved quality of life. Establishing collaborative pilot programs with key opinion leaders and high-volume centers can accelerate adoption curves and generate compelling real-world evidence to support reimbursement negotiations.

Second, strengthening supply chain resilience through diversified sourcing and near-shoring initiatives will mitigate the financial impacts of evolving trade policies. Engaging in joint ventures with regional manufacturing partners can also facilitate market entry in underpenetrated territories. Third, integrating digital health tools into pre- and post-treatment pathways will enhance patient engagement and enable remote monitoring of outcomes, providing a richer data set for both clinical optimization and payer discussions.

Finally, customizing market access strategies to regional regulatory nuances-such as expedited device review programs in the Americas or harmonized EU approval processes-will streamline time to market. By synchronizing clinical development plans with local policy frameworks and reimbursement landscapes, companies can secure favorable positioning and drive sustainable growth across multiple geographies.

Detailing Rigorous Data Collection Analysis and Validation Protocols Ensuring Robustness of Research Findings in Prostatic Hyperplasia Market Assessment

This research employed a rigorous methodology combining comprehensive secondary research with targeted primary interviews and data triangulation. Initially, peer-reviewed journals, regulatory databases, patent filings, and industry white papers were systematically analyzed to construct a robust baseline of therapeutic modalities, device innovations, and policy developments. Historical regulatory approvals and guideline revisions were mapped to identify timing and scope of major market shifts.

Complementing the desk research, structured interviews with leading urologists, interventional radiologists, procurement specialists, and payers provided firsthand insights into clinical preferences, procedural workflows, and reimbursement challenges. Quantitative data points were validated through cross-referencing publicly available clinical trial registries and device approval summaries, ensuring consistency across multiple sources.

Finally, an iterative review process engaged subject matter experts to refine assumptions, resolve discrepancies, and contextualize findings within broader healthcare trends. This layered approach-incorporating secondary evidence, expert validation, and market feedback-underpins the reliability and depth of the strategic insights presented throughout this report.

Synthesizing Key Findings and Strategic Implications to Illuminate Future Directions and Opportunities in the Benign Prostatic Hyperplasia Treatment Arena

Bringing together the key findings reveals a market at the cusp of significant transition. Advances in minimally invasive therapies, alignment of regulatory pathways, and heightened tariff-driven supply chain considerations are collectively reshaping treatment algorithms and competitive dynamics. Segmentation analysis underscores the growing importance of non-surgical interventions and specialized product categories, while regional insights highlight the need for tailored market access strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

The interplay between established pharmaceutical agents and next-generation device platforms points to an integrated future in which combination therapies and digital health solutions drive patient-centered care. For stakeholders eager to navigate this complex ecosystem, the ability to anticipate policy shifts, forge strategic partnerships, and invest in differentiated technologies will determine long-term success. By synthesizing clinical innovation, operational resilience, and market intelligence, industry participants can capture emerging opportunities and deliver impactful outcomes for the growing BPH patient population.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Benign Prostatic Hyperplasia Treatment Market, by Treatment Type

  • 8.1. Medications
    • 8.1.1. 5-Alpha-Reductase Inhibitors
    • 8.1.2. Alpha Blockers
  • 8.2. Minimally Invasive Therapies
    • 8.2.1. Prostate Artery Embolization
    • 8.2.2. Water Vapour Therapy
  • 8.3. Surgical Treatments
    • 8.3.1. Laser Surgery
    • 8.3.2. Prostatic Urethral Lift
    • 8.3.3. Transurethral Incision Of The Prostate
    • 8.3.4. Transurethral Resection Of The Prostate

9. Benign Prostatic Hyperplasia Treatment Market, by Product Type

  • 9.1. Catheters
  • 9.2. Electrodes
  • 9.3. Implants
  • 9.4. Prostatic Stents
  • 9.5. Resectoscopes
  • 9.6. Urology Laser

10. Benign Prostatic Hyperplasia Treatment Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Clinics
  • 10.3. Homecare
  • 10.4. Hospitals

11. Benign Prostatic Hyperplasia Treatment Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Benign Prostatic Hyperplasia Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Benign Prostatic Hyperplasia Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Benign Prostatic Hyperplasia Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Benign Prostatic Hyperplasia Treatment Market

16. China Benign Prostatic Hyperplasia Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Alembic Pharmaceuticals Limited
  • 17.7. Asahi Kasei Corporation
  • 17.8. Astellas Pharma Inc.
  • 17.9. Bayer AG
  • 17.10. Boehringer Ingelheim GmbH
  • 17.11. Boston Scientific Corporation
  • 17.12. Cipla Ltd.
  • 17.13. Coloplast Group
  • 17.14. Dr. Reddy's Laboratories
  • 17.15. Eli Lilly and Company
  • 17.16. Endo International PLC
  • 17.17. GlaxoSmithKline plc
  • 17.18. Hikma Pharmaceuticals PLC
  • 17.19. IPG Photonics Corporation
  • 17.20. Lumenis Ltd.
  • 17.21. Olympus Corporation
  • 17.22. Organon group of companies
  • 17.23. PROCEPT BioRobotics Corporation
  • 17.24. ProstaLund AB
  • 17.25. Quanta System
  • 17.26. Richard Wolf GmbH
  • 17.27. Teleflex Incorporated
  • 17.28. Urologix, LLC.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY WATER VAPOUR THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY WATER VAPOUR THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY WATER VAPOUR THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY LASER SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY LASER SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY LASER SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC URETHRAL LIFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC URETHRAL LIFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC URETHRAL LIFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL INCISION OF THE PROSTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL INCISION OF THE PROSTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL INCISION OF THE PROSTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL RESECTION OF THE PROSTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL RESECTION OF THE PROSTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL RESECTION OF THE PROSTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ELECTRODES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ELECTRODES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ELECTRODES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY RESECTOSCOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY RESECTOSCOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY RESECTOSCOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY UROLOGY LASER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY UROLOGY LASER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY UROLOGY LASER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 156. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 157. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 179. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 180. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 187. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 188. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 189. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)